Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$459.6m

Voyager Therapeutics Management

Management criteria checks 2/4

Voyager Therapeutics' CEO is Al Sandrock, appointed in Mar 2022, has a tenure of 2.17 years. total yearly compensation is $3.17M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $531.01K. The average tenure of the management team and the board of directors is 1.9 years and 4.9 years respectively.

Key information

Al Sandrock

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.7%
CEO tenure2.2yrs
CEO ownership0.1%
Management average tenure1.9yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Voyager Therapeutics hires new finance chief

Sep 07

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Aug 04

Looking Back In On Voyager Therapeutics

Jun 08

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12
Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Voyager Does A Reboot After First Generation Failures

Mar 25

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Feb 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Voyager Therapeutics: Another Year, Another Deal

Nov 21

Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Aug 11
Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts

Jul 18
Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts

CEO Compensation Analysis

How has Al Sandrock's remuneration changed compared to Voyager Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$3mUS$624k

US$132m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$96m

Mar 31 2023n/an/a

US$99m

Dec 31 2022US$7mUS$525k

-US$46m

Compensation vs Market: Al's total compensation ($USD3.17M) is above average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Al's compensation has been consistent with company performance over the past year.


CEO

Al Sandrock (65 yo)

2.2yrs

Tenure

US$3,172,433

Compensation

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He serves as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...


Leadership Team

NamePositionTenureCompensationOwnership
Alfred Sandrock
President2.2yrsUS$3.17m0.12%
$ 531.0k
Robin Swartz
COO, Principal Financial & Accounting Officer and Acting Chief Business Officerless than a yearUS$1.38m0.062%
$ 284.5k
Jacquelyn Sandell
Chief Legal Officerless than a yearUS$1.91m0%
$ 0
Krystof Bankiewicz
Founderno datano datano data
Guangping Gao
Founder & Member of Scientific Advisory Boardno datano datano data
Mark Kay
Founderno datano datano data
Phillip Zamore
Founder & Member of Scientific Advisory Boardno datano datano data
Todd Carter
Chief Scientific Officer1.7yrsno data0.16%
$ 740.5k
Michelle Smith
Chief Human Resources Officer3.7yrsno datano data
Maria Lopez-Bresnahan
Senior Vice President of Translational Medicine & Clinical Development3.8yrsno datano data
Trista Morrison
Chief Corporate Affairs Officer & Chief of Staff to the CEO2.3yrsno datano data
Toby Ferguson
Chief Medical Officerless than a yearno datano data

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: VYGR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Alfred Sandrock
President2.3yrsUS$3.17m0.12%
$ 531.0k
Guangping Gao
Founder & Member of Scientific Advisory Boardno datano datano data
Phillip Zamore
Founder & Member of Scientific Advisory Boardno datano datano data
Dinah Sah
Consultant & Member of Scientific Advisory Board4.9yrsUS$1.81mno data
James Arthur Geraghty
Independent Director10.3yrsUS$263.78k0.10%
$ 461.3k
Glenn Pierce
Independent Director7.3yrsUS$248.78k0.040%
$ 184.1k
Steven Hyman
Independent Director8.7yrsUS$255.78k0%
$ 0
Michael Higgins
Independent Chairman of the Board8.8yrsUS$281.28k0.058%
$ 264.6k
Catherine Mackey
Independent Director1.8yrsUS$250.78k0%
$ 0
David Liu
Member of Scientific Advisory Boardno datano datano data
Grace Colon
Independent Director1.3yrsUS$432.23k0%
$ 0
Nancy Vitale
Independent Director3.7yrsUS$255.28k0%
$ 0

4.9yrs

Average Tenure

65yo

Average Age

Experienced Board: VYGR's board of directors are considered experienced (4.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.